KR20240111011A - 파버병 마커 및 이의 용도 - Google Patents

파버병 마커 및 이의 용도 Download PDF

Info

Publication number
KR20240111011A
KR20240111011A KR1020247022597A KR20247022597A KR20240111011A KR 20240111011 A KR20240111011 A KR 20240111011A KR 1020247022597 A KR1020247022597 A KR 1020247022597A KR 20247022597 A KR20247022597 A KR 20247022597A KR 20240111011 A KR20240111011 A KR 20240111011A
Authority
KR
South Korea
Prior art keywords
cd11b
mhcii
subject
faber
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247022597A
Other languages
English (en)
Korean (ko)
Inventor
크리스틴 코케리
브란테 샘페이
Original Assignee
엔지반트 테라퓨틱스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔지반트 테라퓨틱스 게엠베하 filed Critical 엔지반트 테라퓨틱스 게엠베하
Publication of KR20240111011A publication Critical patent/KR20240111011A/ko
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247022597A 2018-03-27 2019-03-22 파버병 마커 및 이의 용도 Ceased KR20240111011A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862648775P 2018-03-27 2018-03-27
US62/648,775 2018-03-27
KR1020207023065A KR20200136367A (ko) 2018-03-27 2019-03-22 파버병 마커 및 이의 용도
PCT/IB2019/000290 WO2019186272A1 (en) 2018-03-27 2019-03-22 Farber disease markers and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207023065A Division KR20200136367A (ko) 2018-03-27 2019-03-22 파버병 마커 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20240111011A true KR20240111011A (ko) 2024-07-16

Family

ID=66530353

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247022597A Ceased KR20240111011A (ko) 2018-03-27 2019-03-22 파버병 마커 및 이의 용도
KR1020207023065A Ceased KR20200136367A (ko) 2018-03-27 2019-03-22 파버병 마커 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207023065A Ceased KR20200136367A (ko) 2018-03-27 2019-03-22 파버병 마커 및 이의 용도

Country Status (16)

Country Link
US (2) US20190302126A1 (cg-RX-API-DMAC7.html)
EP (1) EP3775924A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021516757A (cg-RX-API-DMAC7.html)
KR (2) KR20240111011A (cg-RX-API-DMAC7.html)
CN (2) CN111971562A (cg-RX-API-DMAC7.html)
AU (1) AU2019244477A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020016435A2 (cg-RX-API-DMAC7.html)
CA (1) CA3090354A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002105A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020010043A2 (cg-RX-API-DMAC7.html)
IL (2) IL311212A (cg-RX-API-DMAC7.html)
MX (1) MX2020008377A (cg-RX-API-DMAC7.html)
PH (1) PH12020551206A1 (cg-RX-API-DMAC7.html)
RU (1) RU2020119065A (cg-RX-API-DMAC7.html)
SG (1) SG11202007508TA (cg-RX-API-DMAC7.html)
WO (1) WO2019186272A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220088158A1 (en) * 2019-01-23 2022-03-24 Aceragen, Inc. Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
CA3209730A1 (en) * 2021-03-29 2022-10-06 Alan Parker Modified adenovirus
CN117647649A (zh) * 2023-08-15 2024-03-05 迈健医药科技无锡有限公司 一种免疫细胞全维分析的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
JP6832158B2 (ja) 2013-03-14 2021-02-24 アイカーン スクール オブ メディシン アット マウント サイナイ 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法
EP3115786A1 (en) * 2015-07-08 2017-01-11 Centogene AG Method for the diagnosis of farber's disease

Also Published As

Publication number Publication date
BR112020016435A2 (pt) 2020-12-15
KR20200136367A (ko) 2020-12-07
MX2020008377A (es) 2020-09-25
CO2020010043A2 (es) 2020-11-10
RU2020119065A (ru) 2022-04-27
PH12020551206A1 (en) 2021-04-19
EP3775924A1 (en) 2021-02-17
CN111971562A (zh) 2020-11-20
SG11202007508TA (en) 2020-09-29
CL2020002105A1 (es) 2020-12-04
CN118112249A (zh) 2024-05-31
JP2021516757A (ja) 2021-07-08
US20190302126A1 (en) 2019-10-03
IL311212A (en) 2024-05-01
WO2019186272A1 (en) 2019-10-03
US20210199670A1 (en) 2021-07-01
AU2019244477A1 (en) 2020-06-25
CA3090354A1 (en) 2019-10-03
JP2023159164A (ja) 2023-10-31
IL276420A (en) 2020-09-30

Similar Documents

Publication Publication Date Title
EP2635299B1 (en) Methods for treating hair loss disorders
JP2023159164A (ja) ファーバー病マーカーおよびその使用
US20250170225A1 (en) Compositions and methods for treating farber disease
WO2016168612A1 (en) Methods for treating myeloproliferative disorders
US20230123505A1 (en) Methods for treating farber disease
US20160009797A1 (en) Methods for regulating hair growth disorders
US6562574B2 (en) Association of protein kinase C zeta polymorphisms with diabetes
WO2001046415A1 (en) Novel tachykinin-like polypeptides and use thereof
US20040213738A1 (en) CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity
HK40105998A (en) Compositions and methods for treating farber disease
JP2002541440A (ja) 記憶の固定を調節する方法及び組成物
WO2001086000A2 (en) Association of dopamine beta-hydroxylase polymorphisms with bipolar disorder
HK1079690A (en) Osteopontin, oligodendrocytes and myelination

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240705

Application number text: 1020207023065

Filing date: 20200810

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240801

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240926

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250402

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D